TriaGen Wealth Management’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$920K Buy
24,006
+256
+1% +$6.71K 0.23% 98
2026
Q1
$504K Buy
23,750
+546
+2% +$10.9K 0.14% 113
2025
Q4
$378K Buy
+23,204
New +$351K 0.1% 137

Other funds holding TXG

TriaGen Wealth Management's TXG Position: Q2 2026 in Review

TriaGen Wealth Management increased its 10x Genomics (TXG) stake by 1.1% in Q2 2026, buying an estimated $6.71K and bringing the position to 24,006 shares worth $920K. The position accounts for 0.23% of the portfolio, ranked #98.

TriaGen Wealth Management first reported a position in TXG in Q4 2025 and has held it in 3 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • TriaGen Wealth Management held 24,006 shares of 10x Genomics worth $920K as of Q2 2026.
  • TriaGen Wealth Management bought 256 10x Genomics shares in Q2 2026, an estimated $6.71K.
  • 10x Genomics made up 0.23% of TriaGen Wealth Management's portfolio in Q2 2026, its #98 holding.
  • TriaGen Wealth Management first reported a position in 10x Genomics in Q4 2025 and has held it in 3 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on TriaGen Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.